| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cocaine-Related Disorders | |||||
| 2 | More general conditions related to this trial | ||||
| Disorders of Environmental Origin | |||||
| Mental Disorders | |||||
| Substance-Related Disorders | |||||
| 3 | Interventions listed in this trial | ||||
| Mazindol | |||||
| 4 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Stimulants | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute on Drug Abuse (NIDA) | |||||
| VA Connecticut Healthcare System | |||||
|
